Circuit-Bio

Platform of Logical Gene Circuits for Cancer Immunotherapy

Health Tech & Life Sciences
Non Active, Feb 2025 ceased to operate
Seed , Israel Founded 2020
LinkedIn
Last updated 2026-06-18
Total raised
Last: 2020-09
Stage
Seed
Founded
2020
Headcount
4
HQ
, Israel
Sector
Health Tech & Life Sciences

About

Circuit-Bio is a synthetic biology company developing a unique platform of logical gene circuits for cancer immunotherapy. The company's platform focuses on generating gene circuits able to locally and accurately produce a combination of multiple immune-stimulating proteins (immunomodulators) exclusively expressed in targeted tumor cells. The circuit selectively converts cancer cells into 'Trojan horses' utilized as an anti-tumor resource that triggers a robust, long-term, anti-tumor immune response. The immunomodulators' output is tightly controlled by two de novo synthetic cancer-specific promoters (SPECS) and specifically enhances a Boolean AND gate, which enables multi-output gene expression only when both synthetic promoters are activated simultaneously. This emerging bio-convergence approach differentiates itself from other immunotherapy treatments by a unique tunable mode of action and therefore can overcome some of the major obstacles arising from the treatment of immunotherapeutic drugs. The circuit modularity can be reflected by the ability to control and adapt each of the circuit components to the treated indication, such as selecting the most effective tumor-specific immunomodulator combination output.

Funding history · 1 round · — total

Q&A

What is Circuit-Bio's primary focus?
Circuit-Bio is a synthetic biology company developing a platform of logical gene circuits for cancer immunotherapy.
When was Circuit-Bio founded?
Circuit-Bio was founded in April 2020.
What is the current status of Circuit-Bio?
Circuit-Bio is currently inactive and ceased to operate in February 2025.
Where is Circuit-Bio headquartered?
Circuit-Bio is headquartered in Ness Ziona, Israel.
How many employees does Circuit-Bio have?
Circuit-Bio has 1-10 employees.
Which investors participated in Circuit-Bio's funding round in September 2020?
FutuRx and RMGP Biopharma Investment Fund participated in Circuit-Bio's funding round in September 2020.
What is Circuit-Bio's primary sector?
Circuit-Bio's primary sector is Health Tech & Life Sciences.
What is the product stage of Circuit-Bio's technology?
Circuit-Bio's product is in the R&D stage.

Team · 1

Founder · Founder & CSO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsConsumersDemographics & FamilyWomen
Business model
B2B

Tags

drug-discoverycancerpharma-companiesbiotechnologypharmaceuticalsimmunotherapywomen-health
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

LinkedInlinkedin.com/company/72431312

Identifiers & details

Founded2020-4
Employees (exact)4
Status reasonNon Active, Feb 2025 ceased to operate